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a b s t r a c t
Pain is frequen t in pat ien ts w ith connect ive t issue diseases
(CTDs), part icu larly those affected by system ic sclerosis (SSc) and
system ic lupus erythematosus (SLE) in which it is virtually
ubiquitous and can have differen t causes. The SLE classification
criteria include pain associated w ith musculoskeletal involve-
m ent , wh ich are frequen t ly the in it ial symptom of SLE and can
include arth ralgia, arth rit is and/or myalgia. Chron ic w idespread
pain , the cornerstone of fibromyalgia (FM), is also frequen t ly
associated w ith CTDs.
Chronic pain has a considerable impact on mental health , and the
professional and fam ily lives of patients. It can be due to many
disorders, but there are few reports concerning its prevalence
during the course of other diseases.
It is essential to identify the origin of pain in CTDs in order to avoid
dangerous over-treatment in patients w ith co-existing w idespread
pain . Effective pain management is a primary goal of patien t
care, although it has not been investigated in detail in patients
w ith SSc.
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In t roduct ion
Connective tissue diseases (CTDs) are characterised by multiple symptoms generally related to
organ injury. One of the most frequent is pain , the perception and threshold of which may be influ-
enced by many biological, psychological and social factors interacting w ith the central and peripheral
nervous systems. It may be acute or chronic: acute pain is often primarily attributable to inflammation
and/or damage to peripheral structures (i.e. nociceptive input), whereas chronic pain (generally
defined as lasting  3 months) is more likely to be due to input from the central nervous system (CNS).
The chronic nature of CTDs such as system ic lupus erythematosus (SLE) and system ic sclerosis (SSc),
which are often associated w ith pain and stress, can also trigger w idespread chronic pain conditions
such as fibromyalgia (FM).
Pain in system ic sclerosis
System ic sclerosis (SSc, also known as scleroderma) is a severe rheumatic condition characterised
by skin thickening and internal organ fibrosis [1] that is classically classified as lim ited cutaneous SSc
(lcSSc), which has rare organ involvement, and diffuse cutaneous SSc (dcSSc), which has a worse
prognosis and is characterised by rapid fibrosis [1,2].
Pain is a ubiquitous problem in SSc, and may be caused by digital ulcers, Raynaud's phenomenon,
skin breakdown, joint contractures and/or gastrointestinal (GI) disrorders [3]. However, despite its
impact on the patients' quality of life, it has not been w idely studied. In a large study published by the
Canadian Scleroderma Research Group, 85%of the 585 patients reported pain , which is correlated w ith
more frequent episodes of Raynaud's phenomenon, active ulcers, worse synovitis, and gastrointestinal
symptoms [4]; other authors have reported sim ilar findings and that they correlate w ith a poor quality
of life [5e7].
SSc and Raynaud's phenomenon
Raynaud's phenomenon (RP) is the most frequent and earliest manifestation of SSc. It is caused by
digital vasospasms usually triggered by exposure to cold or stress, which lead to the three phases of the
classical colour change from white to blue (cyanosis) and then red (erythema), and is frequently
associated w ith pain and sometimes w ith paresthesia, numbness and impaired hand function. It can be
effectively treated by various classes of drugs, whose benefits include a reduction in the frequency and
severity of attacks, and the prevention and/or healing of digital ulcers. The first-line non-pharmaco-
logical treatment of Raynaud's phenomenon involves avoiding or m inim ising exposure to cold, the use
of warm gloves, and avoiding aggravating factors such as smoking and certain drugs, although these
measures are more effective in the case of primary rather than secondary Raynaud's phenomenon.
Pharmacological measures usually start w ith calcium channel blockers but, if these are ineffective,
other options include topical nitroglycerin , and alpha adrenergic or angiotensin receptor antagonists.
In travenous prostacyclin analogues are warranted in severe cases, particularly if there is a threat of
digital ischaem ia, but they are expensive and, as they burdened by substantial risks (including the
induction of severe hypotension), close monitoring is required during their adm inistration. Novel
approaches include the use of endothelin receptor antagonists, phosphodiesterase inhibitors and
statins, although their place in the therapeutic armamentarium remains to be established, and it may
also be possible to combine drugs acting on different target mechanisms, although this may be lim ited
by questions of cost.
Finally, surgical approaches (particularly thoracic sympathectomy) have fallen out of favour,
probably because of improvements in pharmacological treatments [8].
SSc and digital ulcers
Often persistent and recurrent digital ulcers are one of the most frequent and burdensome clin ical
manifestations, and occur in more than 50%of patients. They may simultaneously affect more than one
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finger, and lead to severe pain and function lim itations [9]. The lack of validated guidelines has
prompted a number of researchers to seek the best treatment, and a very recent study published by
Giuggioli et al. tested the initial use of local lidocaine and prilocaine (25 mg of both per gram of 5%
EMLA cream), followed by local and oral morphine depending on the severity of the pain as measured
by means of a 10 cm visual analogue scale (VAS), and found that the deep wound debridement crucial
for healing was better tolerated [10].
SSc and synovitis
Between 40%and 80%of SSc patients complain of musculoskeletal pain , which is more problematic
in patients w ith early diffuse SSc. The pain may not be sufficiently localised to attribute it to a particular
anatom ical location, but a number of pain syndromes have been identified.
1. Tendinitis: Tendon friction rubs mainly affect patients w ith early diffuse SSc. They have a frequency
of 23e65%, but this tends to decline over time [11,12]. They are considered to be associated w ith
more active disease and worse outcomes.
2. Polyarthritis: Between 36%and 80%of pat ien ts complain of polyarth ralgias, which may be more
frequen t in those w ith early SSc, although some studies have found their occurrence
more equally distributed between lim ited and diffuse SSc [13]. The w ide range of art icular and
non-art icular changes observed in radiographs of SSc patien ts go from juxta-art icular osteo-
porosis and join t space narrow ing to frank erosions in the metacarpophalangeal (MCP),
proximal interphalangeal (PIP), and distal in terphalangeal (DIP) join ts, and w rist . It has been
said that bony erosions (main ly in the hands) affect 4e 57% of patien ts who have had SSc for
seven years, and join t space narrow ing affects 16e 92%[14]; however, concern has been raised
that some of the join t space narrow ing may be related to concom itan t osteoarthrit is and not just
SSc.
3. Rheumatoid arthritis (RA): The recent availability of anti-cyclicitrullinated peptide (CCP) assays has
led to the finding that 1e15% of SSc patients have overlapping anti-CCP antibody-positive RA.
However, it should be noted that anti-CCP antibodies alone do not define RA, and it is not known
how many SSc patients w ithout RA are anti-CCP positive.
4. Fibromyalgia (FM): Studies reported that 48% of patients had 11 or more tender points (TPs),
whereas the mean TP count was 7 (of 18) in the Malcarne study [15]. Clinical experience suggests
that FM is not uncommon in patients w ith SSc or other CTDs, and dedicated work is needed in this
field, including studies using the 2010 fibromyalgia criteria.
SSc and gastrointestinal disorders
The gastroin test inal (GI) is the second most frequen tly involved organ system in SSc pat ients
[16], who often experience complicat ions such as gastro-esophageal symptom s, abdom inal
pain and distension, weigh t loss and nutritional deficiencies, diarrhea, incon tinence, and
const ipat ion .
The esophagus is the most frequently affected part of the GI tract, and up to 90%of patients describe
symptoms of heartburn, regurgitation and dysphagia. These dysfunctions are probably due to smooth
muscle atrophy (particularly the inner circular layer of the muscularis propria) and fibrosis affecting the
distal two-thirds of the esophagus but sparing the proximal part that causes the loss of normal neural
function. Lifestyle modifications and the avoidance of exacerbating food groups are often suggested
first , but patients often need intensive treatment w ith proton pump inhibitors to control their
symptoms.
Up to 50% of SSc patients report early satiety, nausea, bloating, and abdom inal discomfort. The
pathophysiology is not clear but it is possible that lymphocyte activation plays an important role in
causing smooth muscle atrophy and collagen deposition, leading to severe ultrastructural alterations in
smooth muscle cells and nerve fibres. It is thought that gut dysfunction relates to a neuropathic process
in SSc patients [16].
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The clin ical management of gastric motility disorders can be difficult because of their poor corre-
lations w ith symptoms. Dietary modifications w ith the addition of a prokinetic agent is often the
mainstay of treatment, and probiotics may be useful in some patients. The use of metoclopram ide can
improve gastric motility and motor activity, and somatostatin analogues such as octreotide have also
been used to induce contractile activity throughout the bowel. It has been reported that up to 18%of
patients w ith SSc are at high risk of malnutrition due to perioral sclerosis, esophageal dysmotility and
abdom inal discomfort; the management of weight loss and malnutrition requires a multidisciplinary
team approach in which dieticians, nutrition specialists and ward nursing staff play a crucial role.
Diarrhea can affect up to 50% of patients, who need to be fully assessed because the cause is
multifactorial. Once the contributory causes of malabsorption have been investigated, symptomatic
approaches such as dietary measures to increase stool consistency and use of loperam ide to inhibit
peristalsis and secretion can be tried; however, caution is required in order to avoid pseudo-
obstruction. Cholestyram ine or other bile salt acid sequestrants may be helpful [16].
The colon and anorectum are the second most frequen tly affected parts of the GI tract , and it has
been suggested that the anorectal dysfunction reported by 50e70% of SSc pat ien ts is due to
neuronal dysfunct ion , smooth muscle atrophy and fibrosis affecting the in ternal anal sphincter.
Fecal urgency can arise because of reduced rectal compliance and capacity due to collagen depo-
sition , and fecal incont inence has a sign ifican tly negat ive impact on the pat ien t 's quality of life.
Pract ical specialist management such as biofeedback and bowel and pelvic floor muscle training can
be offered although the evidence is lim ited. Surgical repair of the anal sphincter has been
at tempted but the long-term outcomes suggest worsen ing of con tinence and so th is approach is not
generally advocated [16].
It has been reported that colon ic involvement occurs in 20e50%of patien ts, who often lack the
post-prandial gastrocolic response mediated by the cholinergic pathway, thus reducing colonic
motility, prolonging colon ic transit and leading to const ipat ion . Unfortunately, laxat ives frequent ly
offer lit t le benefit : st imulan t laxat ives rely on con tact w ith the bowel mucosa, which is unpre-
dictable, and osmot ic laxatives can aggravate bloat ing and discomfort. It has been shown that the
5HT4 receptor agonist prucalopride accelerates colonic transit but , although the results have been
prom ising, they have only been published in case reports. Opioid an tagon ists such as methylnal-
t rexone do not seem to be very beneficial in pat ien ts w ith SSc because of the nature of their bowel
dysmot ility. Biofeedback train ing is useful in the case of idiopath ic const ipat ion , but it has not been
studied in SSc. There are no published data corn ing the effect of sacral nerve st imulat ion (SNS) on
const ipat ion in SSc pat ien ts, although it is useful in idiopath ic const ipat ion ; however, the draw-
backs of SNS are that it is an expensive invasive procedure associated w ith the risks of in fect ion,
lead m igrat ion and pain .
Intestinal pseudo-obstruction is a rare GI manifestation of SSc. The treatment algorithms mention
professional patient counselling, and depressive symptoms have been reported to be associated w ith
GI involvement in SSc patients. Treating gastroenterologists should take an overall holistic approach
and their patients' quality of life, functional status and depressive symptoms, whereas treatment in-
terventions for SSc are lim ited [16].
Pain in system ic lupu s eryth em atosu s
SLE and inflammatory pain
Inflammation is the most frequent cause of pain in SLE patients. It is generally due to inflammatory
arthritis, which is included in the clin ical set of the American College of Rheumatism (ARC) classifi-
cation criteria [17,18]. The arthritis is typically not erosive, does not induce joint deform ity, and
frequently precedes the other manifestations of SLE. It is associated w ith morning stiffness for more
than 30 m in, can be evanescent or persistent, affects the knees and the small joints of hands (PIPs), and
produces objective evidence of inflammation (tenderness, swelling and effusion). A minority of
patients may show deform ing reducible joint involvement of the hands (Jaccoud's arthropathy) [19].
The presence of synovitis is due to the production of cytokines such as interleukin (IL)-6, IL-17,
in terferon (INF) alpha, IL-18, tumour necrosis factor (TNF) and B cell stimulating factor (BSF)-2, which
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main responsible for immune response attivation and tissue damage [20]. The clincal set of the ACR
criteria includes serositis, which may present as painful or painless pleural or pericardial effusion and
ascitis as a result of inflammation of the lin ing of lung, heart, and abdom inal structures. Abdom inal
pain is reported by 8e 40%of SLE patients but may also be due to other causes, including mesenteric
vasculitis and pancreatitis [21,22].
SLE and neuropathic pain
SLE patients show a wide range of central nervous system (CNS) manifestations, including neuro-
psychiatric disorders and syndromes associated w ith the presence of auto-antibodies [23]. Although its
relationship w ith SLE is not clear, headache and m igraine are reported by 32e 66%of SLE patients and
may have various causes, including neuropsychiatric SLE (NPSLE) [24]. A recent study of 40 SLEpatients
found that 70% experienced headache (tension type headache in 37.5%, m igraine in 30%, cluster
headaches in 2.5%, and intracranial hypertension in 5%) but there was no association w ith disease
activity [25,26]. A close association w ith cognitive impairment, depression, pain and fatigue has been
found in NPSLE patients, but the underlying causes are unclear. Auto-antibodies cross-reacting w ith
DNA, N-methyl-D-aspartate receptors, and anti-endothelial and anti-phospholipid antibodies are the
most common factors associated w ith the pathogenesis of NPSLE [27].
It has been shown that peripheral neuropathies may be equally or even more frequent than some
CNS syndromes in SLE patients [28,29], and therefore another source of pain . A recent long-term study
of more than 2000 patients found that the prevalence of peripheral neuropathies was 5.9%, and that
66.7%of these were peripheral neuropathies due to SLE, of which sensory and sensorimotor axonal
polyneuropathies were the most frequent. Small-fibre neuropathies and demyelinating poly-
neuropathies are other causes of peripheral neuropathy in SLE [30].
Neuropathic pain can be also a consequence of herpes zoster (HZ) infection, a painful neuro-
cutaneous disease caused by the reactivation of varicella zoster virus. Immunological studies of SLE
patients have shown abnormal T cell-mediated cytotoxicity, and the suppression of cellular immunity
may be involved in the pathogenesis of virus reactivation [31]. It is known that disease activity and the
use of corticosteroids and/or immunosuppressive therapies contribute to HZ infection, although a
study of a large cohort of SLE patients showed an annual HZ incidence rate of 6.4 events/1000 patient-
years w ithout any association w ith disease activity (SLEDAI <8); post-herpetic neuralgia was detected
in 19%of the patients [32].
SLE and central pain
Musculoskeletal pain is reported by 50e90%SLE of patients during the course of the disease [33]
and chronic w idespread pain , which affects 5e10%of the general population [34], by 65e80%of SLE
patients [35,36]. Until a few years ago, the pain associated w ith many rheumatic diseases was
considered to be peripheral in origin and induced by the well-known mechanisms of acute or chronic
inflammation, or morpho-structural alterations in the involved joints [37,38]. However, the mecha-
nisms underlying chronic w idespread pain (the prototype of which is FM) have only recently been
identified as neurophysiological modifications in the perception, transm ission and, above all, pro-
cessing of nociceptive afferents at the level of the CNS, which seem to be caused by what has come to be
called “sensitisation ” : i.e. a permanent state of neuronal hyperexcitability that involves all of the
peripheral and central structures of the nociceptive system and causes hyperalgesia and allodynia
[39,40]. Immunological cascades may play a role in maintaining central sensitivity and chronic pain ,
which is increased when CNS glial cells release pro-inflammatory cytokines; the traditional dichotomy
of inflammatory vs non-inflammatory pain may therefore be less appropriate than previously thought
[41]. The neurophysiological mechanisms underlying central sensitisation syndromes may also play a
role in causing the painful symptoms characterising CTDs. Patients w ith chronic pain conditions are
generally female and have experienced an early-life trauma or have a personal or fam ily history of
chronic pain , or a personal history of other centrally mediated symptoms (insomnia, fatigue, cognitive
alterations and mood disturbances) and cognitions such as catastrophising, all of which can predict the
likelihood that acute pain w ill become chronic [42,43].
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SLE and fibromyalgia
The clin ical hallmark of FM is chronic w idespread pain and tenderness to palpation of at least 11/18
tender points (TPs) [44]. Various symptoms are characteristically associated w ith FM, such as sleep,
mood and neurocognitive disorders, as indicated by the 2010 ACR classification criteria [45]. The
estimated prevalence of FM in the general population is about 1e3%in different groups [46], and many
studies have investigated its prevalence in SLE patients, and evaluated how concom itant FM can in-
fluence the symptoms and the activity of SLE. Morand et al. [47] found a 25.3%prevalence of FM in a
cohort of 87 SLE patients; Middleton et al. [48] a 22% prevalence in a group of 102 patients; and
Iannuccelli et al. [36] a prevalence of 33%in a cohort of 50 patients. The co-existence of FM may make it
difficult to make a differential diagnosis w ith SLE flares.
The most w idely used indices for objectively measuring SLEdisease activity are the British Isles Lupus
Assessment Group (BILAG) Index, the European Consensus Lupus Activity Measurement (ECLAM), and
the System ic Lupus Erythematosus Disease Activity Index (SLEDAI), but none of these rates pain as such
[49]. The System ic Lupus International Collaborating Clinics (SLICC) group has recently proposed a new
set of criteria that includes the specific clin ical manifestations frequently reported by SLE patients. The
features of arthritis are specified because of the overlap between FM and SLE in some patients and it is
necessary to confirm that there is joint line tenderness and not more diffuse allodynia. It is also necessary
to point out that the cause of all the SLICCcriteria is attributable to SLEand not to another disease process
or condition [50]. Middleton et al. [48] found that SLE patients w ith concom itant FM had significantly
more frequent and severe symptoms, but there were no significant difference in SLE activity measures
between the patients w ith or w ithout FM, and other authors have confirmed the absence of correlations
between concom itant FM and disease activity, joint damage or organ dysfunction [50,51].
Fatigue is another symptom characterising FM and the most common constitutional and
debilitating symptom associated w ith pain in SLE patients [52], w ith prevalence rates of 50e80%[53].
Many studies have failed to demonstrate a correlation between fatigue and SLE disease activity, and
only a few have observed greater disease activity in patients reporting fatigue [36,53,54].Moreover, SLE
patients w ith overlapping FM report symptoms such as headache, morning stiffness, diffuse alopecia,
and arthralgia significantly more often [55].
The health-related quality of life (HRQoL) of SLE patients can be evaluated by adm inistering ques-
tionnaires such as the Short-form 36 (SF-36) [56], and the Patient Acceptable Symptom State (PASS) a
simple questionnaire used to assess well-being in various rheumatic diseases including SLE [57].
Pain is associated w ith anxiety and depression, and perceptions of reduced physical functioning,
and so SLEpatients need psychosocial in terventions to relieve their pain and distress and improve their
coping skills [58]. Pain coping cognitions such as self-efficacy for pain control and pain catastrophising
can influence symptoms such as pain , stiffness, fatigue, and psychological distress in SLE patients.
Recent data demonstrate that patients w ith low levels of self-efficacy for pain control and/or high
levels of pain catastrophising report more physical symptoms and psychological distress, and highlight
the importance of assessing coping constructs in SLE patients [59]. Regardless of FM, pain influences
the quality of life, and SLE patients who have higher pain levels also report stiffness and fatigue. SLE
patients frequently report symptoms such as pain , fatigue and musculoskeletal distress, all of which
are related to low HRQoL scores [60] and cause functional lim itations that lead to a significant
econom ic burden. The working productivity of SLEpatients w ith the highest levels of pain is lower than
that of SLE patients w ith less pain [61]. Consequently increased work absenteeism and work disability
(WD) rates have been observed in numerous SLE studies. The reported WD rates range from 20%to 50%,
and vary w idely among SLE population studies. The demographic factors associated w ith WD include
age, a low educational level, low socio-econom ic status and race, and correlations have been found
between WD and pain , fatigue, depressive symptoms, comorbidities, disease duration and activity,
joint damage and cognitive dysfunction [62]. The differential diagnosis of SLE and FM may be difficult
because the two diseases have some symptoms in common, and low antinuclear antibody (ANA) titres
are frequently reported in the general population and FM patients, thus making it necessary to evaluate
patients clin ically in order to avoid m isdiagnoses.
Although secondary FM is not associated w ith SLE disease activity, it may worsen the quality of life
of patients w ith SLE, and requires appropriate treatment. It is necessary to assess whether pain in SLE
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patients is localised or w idespread, visceral or musculoskeletal. SLE activity should be measured, and
treatment w ith immunosuppressive drugs and steroids should be optim ised on the basis of the
severity of the disease [63,64]. The correct in terpretation of the FM symptoms is crucial to avoid over-
treatment because concom itant FM can simulate SLE flares. Once it has been excluded that the pain is
attributable to disease activity, the same treatment as that used for FM can be adm inistered. Analgesic
drugs such as acetam inophen or tramadol can be safely used in patients w ith w idespread pain and SLE
[65]. Anti-epileptic drugs such as gabapentin and pregabalin have been approved for the treatment of
neuropathic pain: both drugs have favourable safety and tolerability profiles [66], and pregabalin has
also been approved by the American Food and Drug Administration (FDA) for FM. Low doses of tricyclic
antidepressants are useful in the case of musculoskeletal pain and headache. Selective serotonin and
serotonin norepinephrine reuptake inhibitors such as duloxetine (approved by the FDA for FM) can be
used in SLE patients w ith pain and depression [67].
Summ ary
Pain is frequently associated w ith CTDs. The pain in SLE can have various causes (e.g. inflammatory,
neuropathic and central pain), but inflammatory joint pain is one of the most frequent. Chronic w ide-
spread pain is the cornerstone of FM, and many studies have investigated the prevalence of FM in SLE
patients, and evaluated how concomitant FM has a bearing on SLE symptoms and disease activity. The
treatment of pain in SLEpatients requires a differential diagnosis; in particular, it is necessary to establish
whether the pain is localised or w idespread, visceral or musculoskeletal. The first step is to evaluate SLE
activity, and optimise specific SLE treatment w ith immunosuppressive drugs and steroids. FM symptoms
in an SLE patient may be misinterpreted as lupus disease activity and thus lead to over-treatment: when
it has been excluded that SLE activity is the main cause of pain, the treatment is the same as that used for
FM. Analgesic drugs such as acetaminophen or tramadol can be safely used in patients w ith w idespread
pain and SLE. In many cases, non-pharmacological treatments such as aerobic exercise and cognitive
behavioural therapy may also be useful.
Pain is a virtually ubiquitous problem in SSc: 83%of patients in a recent large sample reported
significant pain . Early in the disease process, patients report non-specific muscle pain and stiffness,
whereas other symptoms (e.g. difficulty in swallow ing and gastrointestinal discomfort) emerge as the
disease progresses. Effective pain management is a primary goal of patient care, although it has not
been investigated in detail in patients w ith SSc.
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Pract ice points
  Pain is a cornerstone of the definition of SLE and SSc, but it may be due to a mechanism
related to central pain sensitisation (similar to that observed in FM) and inflammation.
  Inflammatory pain symptoms can be reduced by NSAIDs and DMARDs, but many patients
continue to experience moderate pain due to alterations in central pain regulation mecha-
nisms, as in the case of CWP.
  It is important to identify the symptoms of CWP in order to be able to manage and treat
patients with CTDs appropriately.
  Effective pain management is a primary goal of patient care, although it has not been
investigated in detail in patients with SSc and SLE.
  Researchers and clinicians should be encouraged to assess perceived physical health, health
worries, mental health, and social support, in addition to routinely evaluating organ disease
severity in SSc and SLE patients.
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